TapewireFind a company

person · Reporting owner

Scadden David

Disclosed activity across 4 companies

Tapewire entity
35959
SEC CIK
0001707715

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499DirectorJune 18, 2026June 23, 2026
Carisma Therapeutics Inc.CARM · Entity 74418DirectorJuly 01, 2024July 01, 2024
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813DirectorJune 28, 2022June 30, 2022
Editas Medicine, Inc.EDIT · Entity 5502DirectorJune 17, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common stockSEC Table I · non-derivativeDirect20,419 Reported balance After 2026-06-18 transaction · row 1
1 source row

Row 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 20,419

Restricted stock unitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Restricted stock unitsSEC Table II · derivative / convertible securityDirect2,927 Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18Direct14,950 Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Carisma Therapeutics Inc.

Report date July 01, 2024 · Filed July 01, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2034-07-01Direct38,700 Reported balance After 2024-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-07-01 · Grant · Acquired 38,700 · Balance 38,700

F1: The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.

Dianthus Therapeutics, Inc. /DE/

Report date June 28, 2022 · Filed June 30, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-06-27Direct20,000 Reported balance After 2022-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-06-28 · Grant · Acquired 20,000 · Balance 20,000

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Editas Medicine, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16Direct51,700 Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700

F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2021 Filed May 24, 2021 20:46 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock unit · Derivative 1,585 $0.00 $0.00
Disclosure

SEC source: 0001439222-21-000048 · wf-form4_162188914901072.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,585

Underlying: Common stock · 1,585 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested

F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested

Read SEC document
June 10, 2020 Filed Jun 12, 2020 20:11 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantStock Option (right to buy) · Derivative 11,538 $0.00 Strike: $27.49 $0.00
Disclosure

SEC source: 0001179110-20-007263 · edgar.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Common Stock · 11,538 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest on June 10, 2021.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:22 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 18,188 $0.00 Strike: $9.99 $0.00
Disclosure

SEC source: 0000899243-20-015790 · doc4.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

Read SEC document
May 29, 2020 Filed Jun 1, 2020 21:14 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 1,878 $0.00 $0.00
Disclosure

SEC source: 0001439222-20-000054 · wf-form4_159104604311997.xml · derivative · entry 4

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 1,878 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.

F4 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.

Read SEC document
May 29, 2020 Filed Jun 1, 2020 21:14 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 1,878 Not disclosed Not disclosed
Disclosure

SEC source: 0001439222-20-000054 · wf-form4_159104604311997.xml · nonDerivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,849

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:14 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock units · Derivative 1,686 $0.00 $0.00
Disclosure

SEC source: 0001439222-20-000054 · wf-form4_159104604311997.xml · derivative · entry 3

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,686

Underlying: Common stock · 1,686 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.

F3 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.

Read SEC document
May 28, 2020 Filed Jun 1, 2020 21:14 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock options (right to buy) · Derivative 8,096 $0.00 Strike: $53.35 $0.00
Disclosure

SEC source: 0001439222-20-000054 · wf-form4_159104604311997.xml · derivative · entry 2

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,096

Underlying: Common stock · 8,096 shares

Expires 2030-05-28

F2 · derivative.exercise_date: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021.

Read SEC document
June 07, 2019 Filed Jun 11, 2019 21:12 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 18,188 $0.00 Strike: $13.40 $0.00
Disclosure

SEC source: 0000899243-19-016419 · doc4.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2029-06-06

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders.

Read SEC document
May 31, 2019 Filed May 31, 2019 20:08 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 1,400 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-033626 · doc4.xml · derivative · entry 4

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 1,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
May 31, 2019 Filed May 31, 2019 20:08 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 1,400 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-033626 · doc4.xml · nonDerivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Read SEC document
May 29, 2019 Filed May 31, 2019 20:08 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock units · Derivative 1,878 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-033626 · doc4.xml · derivative · entry 3

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878

Underlying: Common stock · 1,878 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
May 29, 2019 Filed May 31, 2019 20:08 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock option (right to buy) · Derivative 8,919 $0.00 Strike: $47.91 $0.00
Disclosure

SEC source: 0001209191-19-033626 · doc4.xml · derivative · entry 2

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,919

Underlying: Common stock · 8,919 shares

Expires 2029-05-29

F2 · derivative.exercise_date: This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020.

Read SEC document
February 05, 2019 Filed Feb 7, 2019 21:41 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantStock Option (right to buy) · Derivative 23,076 $0.00 Strike: $21.14 $0.00
Disclosure

SEC source: 0001179110-19-001519 · edgar.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,076

Underlying: Common Stock · 23,076 shares

Expires 2029-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2019 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on February 5, 2020 through February 5, 2022.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:36 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries C Preferred Stock · Derivative 16,094 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018341 · doc4.xml · derivative · entry 6

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,228 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:36 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries B Preferred Stock · Derivative 6,429 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018341 · doc4.xml · derivative · entry 5

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,488 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:36 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries A Preferred Stock · Derivative 50,025 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018341 · doc4.xml · derivative · entry 4

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,360 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:36 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 PurchaseCommon Stock 6,600 $15.00 $99,000.00
Disclosure

SEC source: 0000899243-18-018341 · doc4.xml · nonDerivative · entry 2

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,175

F2 · shares: Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:36 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionCommon Stock 28,076 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018341 · doc4.xml · nonDerivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:28 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock units · Derivative 1,400 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-035091 · doc4.xml · derivative · entry 2

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common stock · 1,400 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:28 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock option (right to buy) · Derivative 5,700 $0.00 Strike: $93.50 $0.00
Disclosure

SEC source: 0001209191-18-035091 · doc4.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,700

Underlying: Common stock · 5,700 shares

Expires 2028-05-30

F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019.

Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:43 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 PurchaseCommon stock 200 $83.44 $16,688.00
Disclosure

SEC source: 0001209191-18-020896 · doc4.xml · nonDerivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 571

Read SEC document
June 13, 2017 Filed Jun 15, 2017 21:06 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock option (right to buy) · Derivative 8,000 $0.00 Strike: $50.73 $0.00
Disclosure

SEC source: 0001209191-17-040194 · doc4.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common stock · 8,000 shares

Expires 2027-06-12

F1 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018.

Read SEC document
May 27, 2017 Filed May 31, 2017 20:38 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock option (right to buy) · Derivative 16,000 $0.00 Strike: $48.20 $0.00
Disclosure

SEC source: 0001209191-17-036461 · doc4.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common stock · 16,000 shares

Expires 2027-05-26

F1 · derivative.exercise_date: This option was granted on May 27, 2017. The shares underlying this option vest as to 25% of the underlying shares on May 27, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.